AXS-12 (Reboxetine) Emerging Drug Insight and Market Forecast – 2032

AXS-12 (Reboxetine) Emerging Drug Insight and Market Forecast – 2032

“AXS-12 (Reboxetine) Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about AXS-12 (Reboxetine) for Excessive Daytime Sleepiness (EDS) in the 7MM. A detailed picture of the AXS-12 (Reboxetine) for Excessive Daytime Sleepiness (EDS) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the AXS-12 (Reboxetine) for Excessive Daytime Sleepiness (EDS) . The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AXS-12 (Reboxetine) market forecast, analysis for Excessive Daytime Sleepiness (EDS) in the 7MM, descriptive analysis such as SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Excessive Daytime Sleepiness (EDS).

Drug Summary

AXS-12 (Reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor under development for the treatment of narcolepsy. It modulates noradrenergic activity to promote wakefulness, maintain muscle tone, and enhance cognition. Reboxetine has an extensive safety record in Europe and in over 40 countries, including the US, where it is approved for the treatment of depression. The use of AXS-12 in narcolepsy is supported by positive preclinical and preliminary clinical results. It significantly reduced narcoleptic episodes in hypocretin (orexin)-deficient mice and improved daytime sleepiness with reduced cataplexy in patients with narcolepsy in an open-label pilot trial.

Axsome Therapeutics completed evaluation of AXS-12 in a Phase II clinical trial in patients with Excessive Daytime Sleepiness (EDS) and cataplexy related to narcolepsy. The drug is presently being evaluated in Phase III clinical trials for the treatment of narcolepsy. In August 2020, the company presented Phase II clinical data that showed AXS-12 to rapidly and significantly reduce EDS.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the AXS-12 (Reboxetine) description, mechanism of action, dosage and administration, research and development activities in Excessive Daytime Sleepiness (EDS).

Elaborated details on AXS-12 (Reboxetine) regulatory milestones and other development activities have been provided in this report.

The report also highlights the AXS-12 (Reboxetine) research and development activity in Excessive Daytime Sleepiness (EDS) in detail across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around AXS-12 (Reboxetine).

The report contains forecasted sales of AXS-12 (Reboxetine) for Excessive Daytime Sleepiness (EDS) till 2032.

Comprehensive coverage of the late-stage emerging therapies for Excessive Daytime Sleepiness (EDS).

The report also features the SWOT analysis with analyst views for AXS-12 (Reboxetine) in Excessive Daytime Sleepiness (EDS).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AXS-12 (Reboxetine) Analytical Perspective by DelveInsight

In-depth AXS-12 (Reboxetine) Market Assessment

This report provides a detailed market assessment of AXS-12 (Reboxetine) in Excessive Daytime Sleepiness (EDS) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data sales data from 2025 to 2032

AXS-12 (Reboxetine) Clinical Assessment

The report provides the clinical trials information of AXS-12 (Reboxetine) in Excessive Daytime Sleepiness (EDS) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Excessive Daytime Sleepiness (EDS) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AXS-12 (Reboxetine) dominance.

Other emerging products for Excessive Daytime Sleepiness (EDS) are expected to give tough market competition to AXS-12 (Reboxetine) and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AXS-12 (Reboxetine) in Excessive Daytime Sleepiness (EDS).

Our in-depth analysis of the forecasted sales data of AXS-12 (Reboxetine) data from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AXS-12 (Reboxetine) in Excessive Daytime Sleepiness (EDS).

Key Questions

What is the product type, route of administration and mechanism of action of AXS-12 (Reboxetine)?

What is the clinical trial status of the study related to AXS-12 (Reboxetine) in Excessive Daytime Sleepiness (EDS) and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AXS-12 (Reboxetine) development?

What are the key designations that have been granted to AXS-12 (Reboxetine) for Excessive Daytime Sleepiness (EDS)?

What is the forecasted market scenario of AXS-12 (Reboxetine) for Excessive Daytime Sleepiness (EDS)?

What are the forecasted sales of AXS-12 (Reboxetine) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Excessive Daytime Sleepiness (EDS) and how are they giving competition to AXS-12 (Reboxetine) for Excessive Daytime Sleepiness (EDS)?

Which are the late-stage emerging therapies under development for the treatment of Excessive Daytime Sleepiness (EDS)?